Regeneron Pharma stock (US75886F1075): U.S. law firms launch investigations after May share-price drop

Regeneron Pharma shares remain in focus on Nasdaq after U.S. securities law firms announced investigations into potential claims following a sharp stock decline in mid-May, keeping legal and regulatory risks on the radar for investors in the United States.

Regeneron Pharma is back in the headlines for U.S. investors on Nasdaq after several securities litigation firms disclosed new investigations into potential claims tied to a sharp mid-May share-price decline, putting legal and regulatory risk firmly in focus for the United States-based biotechnology group.

In a press release dated 06/02/2026, Pomerantz LLP said it is investigating claims on behalf of investors of Regeneron Pharmaceuticals after prior news triggered a selloff that saw the stock fall by USD 68.57, or 9.82%, to close at USD 629.68 on 05/16/2026, according to GlobeNewswire as of 06/02/2026.

On the same day, law firm Bronstein, Gewirtz & Grossman also announced that it is investigating potential claims on behalf of purchasers of Regeneron shares and highlighted the same 9.82% move to USD 629.68 on 05/16/2026 as the trigger for its review, according to a separate 06/02/2026 statement reported by Stockhouse as of 06/02/2026.

The dual announcements mean that, as of early June, multiple U.S. plaintiff firms are now scrutinizing the same mid-May stock reaction, underscoring how quickly securities-focused litigation advisers can respond to pronounced price swings in a large-cap U.S. name listed on Nasdaq.

Recent price data show that Regeneron continues to trade actively in the United States after the selloff: the stock changed hands in a range around the low-USD 600s on 06/03/2026 on Nasdaq under the REGN ticker, according to intraday pricing information reported by Moneycontrol for Regeneron Pharmaceuticals as of 06/03/2026.

For investors following the stock from the euro area, the shares can also be accessed via German trading venues such as Tradegate through secondary listings that mirror the Nasdaq quotation in EUR, although trading liquidity and spreads typically remain anchored in the U.S. home market.

As of: 03/06/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Regeneron
• Sector/industry: Biotechnology and pharmaceuticals focused on biologic therapies
• Headquarters/country: Tarrytown, United States
• Core markets: United States, Europe and other international prescription-drug markets
• Key revenue drivers: Approved biologic medicines for eye disease and inflammatory conditions alongside oncology and rare-disease therapies
• Home exchange/listing venue: Nasdaq (REGN)
• Trading currency: USD

Regeneron Pharma: core business model

Regeneron primarily discovers and develops antibody-based medicines that it then commercializes across eye care, immunology, oncology and other specialty areas together with selected partners.

Regeneron Pharma in peer comparison

In the U.S. large-cap biotechnology space, Regeneron Pharma is often compared with companies such as Amgen and Gilead Sciences, which also generate billions of dollars of annual revenue from branded therapies in areas like oncology and immunology and are likewise listed on major U.S. exchanges.

Amgen, another Nasdaq- and NYSE-traded biotech bellwether, reported full-year 2025 revenue in the tens of billions of dollars and maintains a diversified portfolio spanning oncology, inflammation and bone health, according to its latest annual filings on sec.gov dated early 2026, underscoring how scale and breadth help define the peer group into which Regeneron fits.

Gilead Sciences, based in Foster City and listed on Nasdaq under GILD, also sits in the same U.S. biotech cohort with a focus on antivirals and oncology agents, with its most recent earnings releases in 2026 showing a similar reliance on a handful of blockbuster products, according to company results published via its investor relations website and filed with the SEC in the first half of 2026.

Conclusion

The emergence of multiple U.S. law-firm investigations following Regeneron Pharmas 9.82% share-price decline to USD 629.68 on 05/16/2026 keeps legal and regulatory factors in focus alongside the companys scientific and commercial progress.

Set against a peer group of large-cap U.S. biotechs such as Amgen and Gilead Sciences, the situation highlights how abrupt price moves in complex, innovation-driven businesses can quickly attract scrutiny and may influence how investors weigh risk and reward in the sector.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.